Zydus Cadila partners with CHEMI to launch Enoxaparin Sodium Injection in US


Zydus Pharmaceuticals Inc, USA, a fully-owned subsidiary of Cadila Healthcare (Zydus Cadila), has signed a license and supply deal with CHEMI SpA for launching the generic version of Sanofi Aventis’s Lovenox (Enoxaparin Sodium Injection) in the US.

The generic equivalent of Enoxaparin Sodium Injection has been launched in seven dosage strengths. Enoxaparin Sodium Injection is used for prophylaxis of deep vein thrombosis (DVT) in patients who go through abdominal, hip or knee replacement surgery. It is also used for the treatment of acute deep vein thrombosis.

See also  Titagarh Wagons set to rebrand as Titagarh Rail Systems Limited

Enoxaparin works as a blood thinner by generating an antithrombotic effect.

CHEMI SpA, which is based in Italy, is a subsidiary of Italfarmaco Group. As per the agreement, CHEMI will manufacture and supply the Enoxaparin Sodium Injection which will be commercialized in the US by Zydus Pharmaceuticals.

Zydus Cadila partners with CHEMI to launch Enoxaparin Sodium Injection in US

Zydus Cadila partners with CHEMI to launch Enoxaparin Sodium Injection in US. Photo courtesy of Zydus Cadila.

The Italian firm holds proprietary rights on a pharma product made up of Enoxaparin Sodium (Preservative Free) single-use pre-filled syringes, which is an AP-rated generic equivalent of Lovenox.

See also  North Korea teases a terrifying thermonuclear showdown amidst US-South Korea military moves

CHEMI will produce the Enoxaparin Sodium injection within its manufacturing facilities in Italy.

Dr. Sharvil Patel — Managing Director of Cadila Healthcare said: “This partnership between Zydus and CHEMI is another step in our unwavering commitment to improving the supply of critical care drugs, which are vital in delivering quality patient care.

See also  CVC to acquire €3.03bn worth stake in Italian pharma company Recordati

“In addition, this collaboration will bolster the Zydus injectable portfolio and demonstrates Zydus’ long-term commitment to drive growth through investment in complex generic products. We’re proud to be the first Indian company to launch a generic version of Enoxaparin in the United States and are excited about this opportunity.”

In another development, Zydus Cadila, on Friday, said that it was granted the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D vaccine for Covid-19.

Share This